Table 1. Clinico-pathological features of the considered series.
| Total (n = 678) | TNBC (n = 396) | Core Basal (n = 236) | 5NP (n = 143) | p-value (Core Basal vs 5NP) | Non-TNBC (n = 276) | p-value (TNBC vs non-TNBC) | |
| Age (mean±SD) | 54.9±13.2 | 53.8±13.4 | 54.9±13.9 | 53.4±12.7 | n.s. | 56.4±12.8 | n.s. |
| Race | n.s. | n.s. | |||||
| Whyte | 511 (75.4%) | 332 (83.8%) | 194 (82.2%) | 125 (87.4%) | 175 (63.4%) | ||
| African American | 153 (22.6%) | 55 (13.9%) | 36 (15.3%) | 15 (10.5%) | 96 (34.8%) | ||
| Others | 12 (1.8%) | 7 (1.8%) | 4 (1.7%) | 3 (2.1%) | 5 (1.8%) | ||
| Missing | 2 (0.3%) | 2 (0.5%) | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) | ||
| Histotype | n.s. | n.s. | |||||
| ductal | 506 (74.6%) | 311 (78.5%) | 194 (82.2%) | 104 (72.7%) | 191 (69.2%) | ||
| lobular | 44 (6.5%) | 10 (2.5%) | 2 (0.8%) | 7 (4.9%) | 33 (12.0%) | ||
| others | 121 (17.8%) | 68 (17.2%) | 39 (16.5%) | 26 (18.2%) | 52 (18.8%) | ||
| missing | 7 (1.0%) | 7 (1.7%) | 1 (0.4%) | 6 (4.2%) | 0 (0.0%) | ||
| Stage | n.s. | n.s. | |||||
| I | 164 (24.2%) | 114 (28.8%) | 60 (25.4%) | 48 (33.6%) | 50 (18.1%) | ||
| II | 323 (47.6%) | 196 (49.5%) | 119 (50.4%) | 68 (47.6%) | 124 (44.9%) | ||
| III | 110 (16.2%) | 66 (16.7%) | 43 (18.2%) | 21 (14.7%) | 42 (15.2%) | ||
| IV | 6 (0.9%) | 5 (1.3%) | 3 (1.3%) | 2 (1.4%) | 1 (0.4%) | ||
| Missing | 75 (11.1%) | 15 (3.8%) | 10 (4.2%) | 4 (2.8%) | 59 (21.4%) | ||
| Grading | n.s. | <0.001 | |||||
| G1 | 37 (5.5%) | 7 (1.8%) | 2 (0.8%) | 5 (3.5%) | 30 (10.9%) | ||
| G2 | 137 (20.2%) | 38 (9.6%) | 23 (9.7%) | 12 (8.4%) | 97 (35.1%) | ||
| G3 | 481 (70.9%) | 345 (87.1%) | 206 (87.3%) | 125 (87.4%) | 133 (48.2%) | ||
| missing | 23 (3.4%) | 6 (1.5%) | 5 (2.1%) | 1 (0.7%) | 16 (5.6%) |